The Problem: A Broken System of Short-Term Incentives
- The status quo prioritizes short-term treatment over long-term recovery, with fee-for-service models and fragmented funding failing to support continuity, coordination, or evidence-based care.
- Value-based care models are emerging as a solution, offering bundled payments, monthly care management fees, and outcome-based bonuses that align financial incentives with sustained recovery.
- Contingency management—paying patients for abstinence—is highly effective but underutilized due to regulatory and reimbursement barriers; California’s Medicaid pilot sets a promising precedent.
- Bundled and capitated payment models like ARMH support holistic, multi-year care, funding peer support, recovery coaching, and relapse management that traditional systems exclude.
- Policy action is urgently needed to enforce parity, enable contingency management, expand data infrastructure, and fund provider transitions—building a reimbursement system that rewards outcomes, not volume.
Addiction remains one of the costliest public health crises in the U.S., yet reimbursement for treatment continues to misalign incentives across patients, providers, and payers. Fee-for-service (FFS) models reward volume over outcomes, while short-term funding and restrictive insurance practices create major barriers to sustained care. Patients are often discharged after detox or brief treatment, with little support for long-term recovery. Medication-assisted treatments (MAT), peer coaching, and recovery housing—proven interventions—are frequently excluded from reimbursement, especially in Medicaid programs that impose arbitrary limits or deny claims.
Fragmentation worsens the issue. Behavioral health “carve-outs” separate addiction care from general medical coverage, complicating care coordination. Parity laws meant to ensure equal mental health coverage remain poorly enforced, and grant-based funding—often the only support for early intervention—can be volatile. The 2025 federal freeze of COVID-era grants left many programs shuttered, highlighting the fragility of relying on unstable funding.
A Turning Point: Value-Based Care (VBC) in Addiction Treatment
Momentum is building to replace fragmented, reactive payment models with value-based care structures that reward outcomes. Several innovative frameworks are emerging:
- P-COAT Model: A bundled payment for opioid addiction treatment that includes MAT, psychosocial support, and care coordination, tied to quality benchmarks.
- Medicaid Health Homes for OUD: States like Vermont and Maryland pay providers a per-member-per-month (PMPM) fee to manage care holistically, enabling flexibility for services like peer support and outreach.
- Outcome-Based Incentives: States are piloting bonuses for treatment retention, abstinence milestones, and integration with physical health services.
Key challenges include defining fair and measurable outcomes, adjusting payments for risk, and addressing the complexity of relapse. Promising models include tiered PMPM payments (higher during intensive early treatment, lower during maintenance) and milestone-based bonuses (e.g., $2,000 for twelve months of remission).
Scaling Evidence-Based Models: Contingency Management, Bundles & Emerging Therapies
Contingency Management (CM)—the use of small financial rewards for sobriety—is among the most effective treatments for stimulant use disorder, yet remains underutilized due to reimbursement gaps and regulatory hesitations. California’s Medicaid program pioneered CM funding through a 24-week incentive program, allowing patients to earn up to $599 in gift cards for negative drug tests. This model offers high ROI by reducing emergency visits and relapse.
Bundled Payments further promote care continuity. For example, Medicare’s weekly payment to opioid treatment programs (OTPs) consolidates medication, counseling, and drug testing into one payment. State Medicaid programs are also moving toward bundled options for intensive outpatient programs, improving provider stability. The Addiction Recovery Medical Home (ARMH) model goes further by bundling payments over a multi-year recovery journey, aligning payments with long-term outcomes and funding services like peer coaching and recovery housing.
Emerging therapies—including pharmacogenomic testing, psychedelic-assisted treatment, and long-acting addiction medications—must also be reimbursed appropriately. Early steps include Medicare coverage for some genetic tests and new CPT codes for psychedelic therapy. Payers should prepare bundled or case-rate models to make these treatments accessible as evidence grows.
Policy Levers and Recommendations
To align incentives and sustain meaningful reform, the following actions are essential:
- Strengthen Parity Enforcement: Eliminate administrative hurdles and ensure addiction services are treated on par with medical services across all payers, including Medicare.
- Expand Federal Demonstrations: Launch CMMI pilots for value-based addiction care to gather outcome data and validate scalable models.
- Modernize CM Regulations: Provide safe harbor under anti-kickback rules to allow meaningful patient incentives for evidence-based treatment adherence.
- Invest in Data Infrastructure: Develop national platforms to track outcomes and inform reimbursement decisions based on standardized metrics (e.g., 6-month abstinence, ER avoidance).
- Support Providers: Offer grants and technical assistance for small providers to adopt new payment models, invest in EHRs, and manage reporting requirements.
- Incentivize States: Provide enhanced federal matching funds to states that implement bundled payments, pay-for-performance, or ARMH-like models.
Conclusion: A New Financial Architecture for Recovery
Addiction is a chronic disease, yet our reimbursement system treats it as an acute episode. Reforming this structure means shifting from fee-for-service to value-based models that fund long-term recovery, reward outcomes, and align incentives across stakeholders. Bundled payments, contingency management, and outcome-based bonuses are not just policy innovations—they are moral imperatives to build a system that supports healing, not just treatment. With the right investment and alignment, we can build a sustainable ecosystem where addiction care is equitable, effective, and financially viable.
